Jordan-based firm MS Pharma has announced a deal with Bioeq that will give it exclusive rights in the Middle East and North Africa region to the FYB201 proposed biosimilar rival to Lucentis (ranibizumab) that has been developed through a partnership between Bioeq and Formycon.
Under the terms of the agreement, MS Pharma will be responsible for registering and commercializing FYB201, with the company indicating that it plans to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?